Joseph Franses, MD, PhD

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.